. 2012 May 12;13(Suppl 2):31–70. doi: 10.1007/s10194-012-0437-6

Table 8.

Drugs for the preventive treatment of migraine with a level of recommendation III and IV

Drug	Route of administration	Daily dosage (mg)	Level of evidence	Scientific strength of evidence	Clinical effectiveness	Adverse events	Level of recommendation
SNRI and SSRI
Fluoxetine	os	10–40	B	+	+	Frequent, not severe	III
Venlafaxine	os	75–150	B	+	+	Occasional, not severe	III
Angiotensin inhibitors
Lisinopril	os	5–20	B	+	+	Occasional, not severe	III
Candesartan		16	B	++	+	Rare, not severe	III
Antiepileptic drugs
Lamotrigin	os	50–200	B	++	+++ (only migraine with aura)	Occasional, not severe	III
5HT₁ antagonists
Methysergide		2–8	A	+++	++	Potentially severe	III^a
Other drugs
Ribloflavin		400	B	++	+	Rare, not severe	III^b
Magnesium		400–600	B	++	+	Rare, not severe	III^b
Petasites hybridus		100–150	B	++	+	Rare, not severe	III^c
Tanacetum parthenium		18.75	B	+	0/+	Rare, not severe	III^c
Thiotic acid		600	B	+	?	Rare, not severe	III^c

^aNot available in Italy

^bNot available in Italy at the recommended dosages

^cAvailable in Italy as a herbal product or as an over-the-counter product